In addition to cell surface membranes, numerous G protein-coupled receptors (GPCRs) are located on intracellular membranes including the nuclear envelope. Although the role of numerous GPCRs at the cell surface has been well characterized, the physiological function of these same receptors located on intracellular membranes remains to be determined. Here, we employ a novel caged Ang-II analog, cAng-II, to compare the effects of the activation of cell surface versus intracellular angiotensin receptors in intact cardiomyocytes. When added extracellularly to HEK 293 cells, Ang-II and photolysed cAng-II increased ERK1/2 phosphorylation (via AT1R) and cGMP production (AT2R). In contrast unphotolysed cAng-II did not. Cellular uptake of cAng-II was 6-fold greater than that of Ang-II and comparable -3]. Intracellular GPCR signalling adds yet more complexity and selectivity to the system, as 1) a GPCR located on an intracellular membrane may serve a role that is distinct from the same receptor located at the cell surface and 2) there maybe be restrictions on which ligands can access its intracellular versus cell-surface receptor.
Introduction
Originally thought to functioning as simple on-off switches that are activated upon ligand binding, the biology of G protein-coupled receptors (GPCRs) is now known to be much more elaborate. GPCRs are now known to couple to various effector molecules in a ligand-dependent manner. This process is currently referred to as biased ligand signalling and provides additional insight into the complex and dynamic nature of GPCR signalling. To date, most models consider the receptor to be located on cell surface membranes when ligand binding initiates signalling.
However, numerous GPCRs have been shown to localize to intracellular membranes such as nuclear and mitochondrial membranes in different primary cell systems, including cardiac myocytes, endothelial cells, vascular smooth muscle cells, neurons, hepatocytes, and kidney cells [1] [2] [3] . Intracellular GPCR signalling adds yet more complexity and selectivity to the system, as 1) a GPCR located on an intracellular membrane may serve a role that is distinct from the same receptor located at the cell surface and 2) there maybe be restrictions on which ligands can access its intracellular versus cell-surface receptor.
To access intracellular receptors, ligands must enter the cell. However, the nuclear envelope comprises a double bilayer, comprising the inner (INM) and outer nuclear membranes (ONM), the lumen of which is referred to as the perinuclear space or nuclear cisternae. Based on their biosynthesis and trafficking, GPCRs are likely oriented in the nuclear membrane with their ligand-binding site facing into the perinuclear space and their effector-binding domains facing either the cytosol or the interior of the nucleus. Hence, ligands must access the perinuclear space in order to reach their binding site on nuclear GPCRs. Hydrophobic ligands, such as prostaglandins, can cross membranes to access intracellular receptors. However, hydrophilic ligands require the presence of some form of active or passive transport mechanism in order to cross both the plasma and nuclear membranes. Ligand-mediated receptor internalization and translocation to the nucleus has been demonstrated for AT 1 [4] . In contrast, PGE 2 and catecholamines are taken up by specific transporters [5] [6] [7] . In both neonatal and adult cardiomyocytes, the effects of extracellular phenylephrine are mediated, in part, by intracellular α 1 AR [7] [8] [9] and extracellularly applied [ 3 H]norepinephrine accumulates within the nuclei of neonatal ventricular cardiomyocytes [10] . Hence, hydrophobic ligands that are able to cross the plasma membrane may show no selectivity for activating cell surface or intracellular signalling.
Catecholamines, for example, can cross both the plasma membrane and nuclear membranes, thus having free access to both cell surface and nuclear receptors, in ventricular myocytes via the extraneuronal monoamine transporter (EMT/OCT3) [6] . In contrast, at least in cardiac cells, extracellular peptidergic ligands such as endothelin-1 and angiotensin II do not appear to be able to access intracellular receptors. In the case of Ang-II, numerous labs have demonstrated the presence of an intracellular renin-angiotensin system (RAS) that allows for the intracellular production of Ang-II.
Several approaches can be employed to activate intracellular receptors in intact cells. For example, cell-permeable ligands, in conjunction with impermeable antagonists to block cellsurface receptors [7] . In the case of peptidergic agonists, molecular approaches can be employed to increase intracellular ligand levels. However, these approaches would be more suited to observe slow changes, such as morphology. To obtain a degree of spatial and temporal resolution, or when using ligands with poor cell permeability, biologically active molecules can be pressure-injected [11] or modified by the incorporation of a "caging" moiety [12] : an easily removable functional group that both increases cell permeability and reduces affinity of the ligand for its cognate binding site. This approach has been used to study the actions of a range of molecules, including ATP [13] , GTP [14] , endothelin-1, [15, 16] , isoproterenol [17, 18] , phenylephrine [19] , γ-aminobutyric acid [20] , urotensin II [21] , endothelin receptor antagonists [16] , IP 3 [22, 23] , cofilin [24] , DNA [25] and RNA [26, 27] into in HEK 293 cells using polyethylenimine (PEI) at a final concentration of 9 µg/ml [29] .
Assays were carried out 48 h after transfection.
ERK1/2 Phosphorylation
HEK 293 cells seeded in uncoated 6-well plates were transfected with either AT1R-Venus or AT2R-Venus as described above. Cells were serum-starved for 24 h prior to stimulation. On the day of the experiment, cells were washed twice with serum-free DMEM and the assay was initiated by adding the indicated ligands and incubated at 37 °C. To terminate the incubation, cells were placed on ice, the medium was removed, and then cells were washed twice with ice-cold PBS. They were then scraped into ice-cold lysis buffer (25 mM Na-HEPES (pH 7.4), 150 mM NaCl, 25 mM NaF, 10 mM MgCl 2 , 1 mM EGTA, 1 mM Na 3 VO 4 , 0.025% sodium deoxycholate, 10% glycerol (v/v), 10 µg/ml leupeptin, 10 µM benzamidine, 0.5 µM microcystin LR, 1% Triton X-100 (v/v), 0.1 mM phenylmethylsulfonyl fluoride and 5 mM dithiothreitol).
After incubating on ice for 30 min, lysates were cleared by centrifugation at 10000 ×g for 10 min, and the supernatants retained. The protein concentration of each lysate was determined, before being denatured using Laemmli sample buffer, and resolved by electrophoresis on SDSpolyacrylamide gels (SDS-PAGE, 10% acrylamide gels). Proteins were transferred onto polyvinylidene difluoride membranes, probed with a phospho-ERK1/2-specific antibody (Cell Signaling Technology) and then, after stripping the membranes with Re-blot Plus mild antibody stripping solution (Millipore), re-probed using an ERK1/2-specific antibody (Abcam) to assess the total ERK immunoreactivity. Horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Inc.) were used and immunoreactive bands were revealed by chemiluminescence and quantified using the Quantity One 1-D analysis software (Bio-Rad Laboratories).
Live-Cell Fluorescence Imaging
To and in the absence or presence of cAng-II, as described previously [16] . Cardiomyocytes were washed three times, stained with a live-cell-permeant DNA dye (DRAQ5; 1 µM) and used for Ca 2+ imaging within 1 h. Images were obtained using a Zeiss LSM 7 Duo microscope (combined LSM710 and Zeiss Live systems) with a 63x/1.4 oil Plan-Apochromat objective. Fluo-4AM was excited using a 488-nm/100 mW diode (1-5% laser intensity) and fluorescence emitted between 495 nm and 550 nm was collected. Cells were scanned at 30 fps in bi-directional mode. The pixel size was set at 0.2 µm and the pinhole at 1.5 Airy units. After establishing a baseline, cAng-II was photolysed by a 70-mW pulse of UV-light using a 405-nm/30 mW diode. The power output from the 405-nm diode was measured at the level of the stage using an EC PlanNeofluar 10x/0.3 objective lens using an X-Cite XR2100 optical power measurement system (Lumen Dynamics Group Inc.). DRAQ5 emissions were used to focus the UV-laser into a 60- 
Canine Cardiomyocyte Isolation
Cardiac cell isolation was performed by perfusion with Tyrode's solution containing collagenase (100 U/mL, Worthington, type II) as previously described [30] .
Statistical Analysis
Data are from a minimum of 3 independent experiments and are presented as mean ± SEM.
Student's t-tests (for single 2-group comparisons) , 1-way or 2-way ANOVA with Bonferroni post hoc test (multiple groups with a common control) were used for statistical comparisons and P<0.05 or less was considered to be statistically significant. Analyses were performed using Prism version 6.0f for Mac OS X (GraphPad Software, La Jolla California USA)
Results

Synthesis of a Photoactivable Caged Ang-II Analog
To permit acute activation of intracellular angiotensin receptors in intact primary cardiac cells, without activating the angiotensin receptors at the cell surface, a caged analog of Ang-II was synthesized. A photo-labile 4,5-dimethoxy-2-nitrobenzyl (DMNB) group was incorporated onto the aromatic side chain of tyrosine-4 as described previously [12, 28] . To be of use in studying signalling in intact cells, a caged Ang-II (cAng-II) analog must possess the following characteristics (relative to unmodified Ang-II): 1) reduced affinity and efficacy for ATR1 and ATR2 activation, 2) increased cell permeability, 3) release of the active form of the ligand upon uncaging.
Characterization of the cAng-II
The inability of the caged Ang-II analog (in the absence of uncaging) to activate cell- min) was 2-fold greater than vehicle-treated cells (Figure 2) . In contrast, 10 nM cAng-II had no effect on the cGMP levels. Upon uncaging, 10 nM cAng-II increased the cellular cGMP content by 2-fold. UV irradiation alone had no effect. An AT2R-selective antagonist, PD 123319, prevented both Ang-II and photolysed-cAng-II from increasing cGMP levels. Similarly, preincubating HEK 293 cells with the non-selective NO synthase inhibitor L-NAME attenuated the increase in cGMP induced by both Ang-II and photolysed-cAng-II. Hence, at a concentration of 10 nM, cAng-II alone was unable to activate AT2R without prior photolysis.
Cell Permeability of cAng-II
In the context of studying intracellular receptor function, one of the requirements of the caging moiety is that it increases the ability of the ligand to access the interior of the cell. (Figure 3) . Thus, cAng-II shows greatly enhanced cell permeability relative to Ang-II.
Cell surface and nuclear Ang-II receptors differ in their ability to regulate [Ca 2+ ] n
cAng-II is cell permeable, unable to activate AT1R or AT2R at concentrations on the order of 10 nM, but regains its pharmacological activity upon photolysis with UV radiation. Hence, cAng-II is a suitable reagent to employ to compare the functional effects of activation of cell surface angiotensin receptors with these same receptors located on the nuclear membrane in intact cells. We have shown previously that Ang-II alters transcription and releases Ca 2+ from perinuclear stores in nuclei isolated from adult hearts and adult cardiomyocytes [32] . Hence, we employed these two experimental endpoints to compare and contrast the effects of activating cell surface versus nuclear Ang-II receptors. In adult cardiomyocytes, photolysis of intracellular cAng-II produced increases in both NF-κB mRNA and 18S rRNA that were similar to those induce by addition of Ang-II to the extracellular media (not shown, [28] 
Discussion
The presence of functional Ang-II receptors on the nuclear membrane suggests that GPCR signalling may occur on intracellular membranes [33] . Cardiomyocytes express angiotensinogen, angiotensin converting enzyme (ACE), and renin [34] [35] [36] . Thus, all of the components required for the production of Ang II are present within cardiomyocytes. In addition, there is evidence suggesting that intracellular Ang II (iAng II) is involved in cardiomyopathy. Ang-II immunoreactivity is increased 3-fold in cardiomyocytes and cardiac endothelial cells from patients with type 2 diabetes and a further 2-fold increase is detected in diabetic patients who are also hypertensive [37] . Elevated glucose increases iAng II in rat neonatal and adult cardiomyocytes [38, 39] , fibroblasts [40] , vascular smooth muscle cells (VSMC) [41] , and mesangial cells [42] . Furthermore, cardiomyocytetargeted overexpression of Ang-II or angiotensinogen in mice increases iAng-II and induces hypertrophy [43, 44] : this elevated iAng-II is not associated with increases in blood pressure or plasma Ang-II concentrations and the resulting hypertrophic effect is no prevented by the AT 1 antagonist losartan [43] . Hence, the chronic activation of intracrine Ang-II signalling may be sufficient to induce hypertrophy; however, the regulation of iAng-II biosynthesis and the means whereby it accesses nuclear ATRs are currently not well understood.
There may be cell-type differences in iAng-II signalling. A splice variant of renin lacking the secretion signal sequence has been demonstrated in rat heart: this variant would be expected to function exclusively within cardiac cells [36] . Similarly, as mentioned above, ACE immunoreactivity has been detected within the nuclei of rat cardiomyocytes, fibroblasts, and mesangial cells [45, 46] . It remains to be determined if Ang-II receptors are only found on the nuclear membrane in cells that are able to produce Ang-II endogenously. In cell types lacking the ability to produce iAng-II, the consequences of physiological or pathological conditions that alter iAng-II production may be negligible. Similarly, the function of a pharmacological agent may be modified by its ability to access intracellular receptors. The ability of phenylephrine to induce hypertrophy in neonatal cardiomyocytes is inhibited by a cell-permeable α-adrenoceptor antagonist but not by a cell-impermeable antagonist. Thus, the physiological function of nuclear GPCRs may be influenced by 1) the cell-types that traffic a particular receptor, or receptor subtype, to the nuclear membrane, 2) the presence of a mechanism whereby the ligand for the receptor can access its cognate ligand binding site when oriented towards the lumen of the nuclear envelope, and 3) the effector molecules coupled to, and regulated by, the cell surface and nuclear receptors. Furthermore, having taken these factors into consideration, a therapeutic agent may have markedly different pharmacological effects depending upon which population of receptors it is capable of accessing: a prodrug, analogous to a caged ligand, that is converted to its pharmacologically active form within the cell, may offer exciting new possibilities for therapeutic intervention in the case where the physiological function of the intracellular receptor is distinct from that of the same receptor, or receptor subtype, at the cell surface ( Table 1) .
Concluding Remarks
In summary, incorporating a photosensitive 4,5-dimethoxy-2-nitrobenzyl (DMNB) group into Ang-II resulted in a caged Ang-II analog that is effectively inactive towards both AT1R and AT2R and cell permeable but easily converted back to active Ang-II upon irradiation with UV. 17
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